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Abstract
Prostate cancer research is hampered by the lack of in vivo preclinical models that accu-
rately reflect patient tumour biology and the clinical heterogeneity of human prostate cancer.
To overcome these limitations we propagated and characterised a new collection of patient-
derived prostate cancer xenografts. Tumour fragments from 147 unsupervised, surgical
prostate samples were implanted subcutaneously into immunodeficient Rag2-/-ȖC-/- mice
within 24 hours of surgery. Histologic and molecular characterisation of xenografts was
compared with patient characteristics, including androgen-deprivation therapy, and exome
sequencing. Xenografts were established from 47 of 147 (32%) implanted primary prostate
cancers. Only 14% passaged successfully resulting in 20 stable lines; derived from 20 in-
dependent patient samples. Surprisingly, only three of the 20 lines (15%) were confirmed
as prostate cancer; one line comprised of mouse stroma, and 16 were verified as human
donor-derived lymphoid neoplasms. PCR for Epstein-Barr Virus (EBV) nuclear antigen,
together with exome sequencing revealed that the lymphomas were exclusively EBV-asso-
ciated. Genomic analysis determined that 14 of the 16 EBV+ lines had unique monoclonal or
oligoclonal immunoglobulin heavy chain gene rearrangements, confirming their B-cell origin.
We conclude that the generation of xenografts from tumour fragments can commonly result
in B-cell lymphoma from patients carrying latent EBV. We recommend routine screening, of
primary outgrowths, for latent EBV to avoid this phenomenon.
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Introduction
The limitations of current preclinical models are increasingly cited as a key cause of the low
success rate of oncology drug development [1]. Traditionally, preclinical models of prostate
cancer are cell lines cultivated in monolayer or xenografts derived from them. Unlike other
solid tumours, few prostate cell lines are available and as such do not represent the heterogene-
ity and complexity of this disease. Indeed, preclinical efficacy of anticancer agents has rarely
translated into clinical efficacy [2]. A key consideration is the length of time these cell lines
have been in culture, undergoing extensive adaptation and selection. Patient-derived xenograft
(PDX) models, based on direct implantation of fresh cancer tissue specimens into immunode-
ficient mice have become reliable models for preclinical research in many types of cancer [3].
PDXs are reported better predictors of response and retain the cellular heterogeneity, architec-
ture, and molecular characteristics of the original cancer [4], offering the possibility of indi-
vidualized cancer treatment, guided by molecular profiling of the PDX. In contrast to other
tumour types, prostate cancer xenografts are notoriously difficult to establish [5]. The reasons
for that are complex and are most likely due to poor sampling of the tumour, the strain of
mouse, engraftment site and cell rather than tissue engraftment. Some investigators have suc-
cessfully generated xenografts from purified populations of cells from human cancers [6–8],
using mouse strains deficient in both innate and adaptive immunity [9], but the majority gen-
erate xenografts from tissue fragments [10]. Supplementing mice with androgens and the use
of mouse embryonic mesenchyme has improved engraftment efficiency [11], but the biggest
improvement has been the development of mice lacking natural killer (NK) T cells, particularly
for tumours that are particularly difficult to establish as a xenograft [10]. Despite these im-
provements, there are very few prostate cancer PDX lines available that are ‘near-patient’ and
from the primary disease [12].
The goal of this study was to generate a panel of prostate cancer xenografts as preclinical
models for drug screening and biomarker development. To improve efficiency we implanted
tumour fragments into the immunocompromised Rag2-/-čC-/-mouse. Here we report on the
characterisation of a panel of 20 stable PDXs lines. After careful validation we established that
only 15% (3/20) were typical of prostate cancer.
Material and methods
Generation of xenografts
All animal work was approved by the University of York Animal Procedures and Ethics Com-
mittee and performed under a United Kingdom Home Office License (POB5AE607). Rag
2tm1.1Flv Il2rg tm1.Flv also known as Rag2-/- čc-/-mice were bred in the Biology Service facility
(BSF), Department of Biology, University of York. The mice used for xenografts were between
6–8 weeks old.
Human prostatic tissue was obtained from 147 adult patients undergoing radical prostatec-
tomy and trans-urethral resection (TUR) for prostate cancer, with informed written consent
(NHS Research Ethics Approval (REC) 07/H1304/121). Some patients had undergone andro-
gen-deprivation therapy prior to TUR. The specimens were sectioned and examined by
pathologists for histological analysis subsequent to xenografting. Tissue pieces were grafted
subcutaneously into recipient Rag2-/-čC-/-mice. Biopsies from hormone naïve patients, mice
were engrafted with 90 day hormone release pellets (12.5mg of 5ċdihydrotestosterone; DHT)
at the time of tissue implantation. Mice were bred in our facility, and were housed in individu-
ally ventilated cages. Once tumours reached 1.5cm3 (considered a humane endpoint) the mice
were sacrificed (by cervical dislocation) and the tumours were either re-implanted (under
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anaesthesia) into further mice or the tissue was processed for further experiments. To maintain
the tumour xenograft as ‘near-patient,’ tumours were re-established from frozen cells after 5
passages in mice. Single cells were isolated from xenograft tumours as previously described
[13]. However, in this study mouse cells were further depleted using the Mouse Cell Depletion
kit (Miltenyi Biotec; cat # 130-104-694) with 98±2% purity.
Histologic evaluation of xenografts
Transplanted tumours were fixed in 10% neutral buffered formalin, paraffin-embedded, and
haematoxylin-eosin (H&E) stained as described previously [13]. Primary outgrowths were
analysed by immunohistochemistry for expression of clinically-relevant biomarkers (androgen
receptor (AR); polyclonal N-20 (Santa Cruz Biotechnology) & clone 441 (ThermoFisher Scien-
tific), prostate specific antigen (PSA) clone 28/A4; Abcam, human pan cytokeratin (clones C-
11, PCK-26, CY-90, KS-A13, M20, A53-B/A2; Sigma-Aldrich) and chromogranin A (clone
LK2H10; Invitrogen). Prostate tissue, from patients with BPH and cancer, was used as a posi-
tive control for each antibody tested. Non-specific binding was assessed using isotype controls
and secondary only antibodies.
Flow cytometry
Cells harvested from xenografts were analysed for the expression of human CD44 (clone
DB105; Miltenyi Biotec), human CD24 (clone 32D12; Miltenyi Biotec), human EpCAM (clone
CD326; Miltenyi Biotech), human B lymphocyte antigen, CD19 (clone HIB19; eBioscience),
human neural cell adhesion molecule, CD56 (clone AF12-7H3; Miltenyi Biotec) and human
CD45 (clones H130 and 2D1; eBioscience) following mouse cell depletion (Miltenyi Biotech).
All cells were analysed on a Cyan ADP flow cytometer (Dako Cytomation) and data pro-
cessed using Summit v4.3 software (Beckman Coulter). Based on flow cytometric analysis we
estimated>98% of cells were donor-derived.
Short tandem repeat (STR) profiling
Xenografts were validated as unique to the patient donor by short tandem repeat (STR) DNA
fingerprinting using the Promega Powerplex 16 system, according to the manufacturer’s
instructions (Promega). The STR profiles of all xenografts were matched to their respective
lymphocyte DNA.
Androgen deprivation therapy
Androgen ablation was carried out on intact mice, supplemented with 12.5mg 5ċ- DHT; Inno-
vative Research of America). 90 day release pellets were sutured in place 2 weeks before inocu-
lation of cells. In vivo efficacy was determined in mice carrying serially-transplantable human
tumour xenografts. Single cells were generated from xenografts, as previously described, and
Rag2-/-čC-/-mice were inoculated with 104–105 tumour cells. Once tumours reached approxi-
mately 500 mm3 in volume, the 5ċDHT pellet was replaced with those continuing either Fluta-
mide or placebo, and mice were randomized to treatment and control arms (http://www.
randomization.com) for blinded assessment of tumour volume.
Tumour volume was evaluated twice per week by caliper measurement using the formula;
tumour volume = (length x width2)/2. Relative tumour growth inhibition/regression was calcu-
lated as follows: T/C = (Ti-T0/Ci-C0). Ti and Ci represent tumour size, of treatment and control
group respectively, at the end of the experiment; T0 and C0 represent tumour size at initiation
of experiment. Tumour response was also calculated using a rate-based T/C measurement
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which uses all the data and is based on the ratio of the fitted growth rates. Power analysis was
used to calculate a sample size of 8 animals per group (with 90% power and a significance level
of 5%).
Cell lines
The cell lines used in this study were obtained from the European Collection of Authenticated
Cell Cultures (ECACC). 22RV1 (Cat. # 05092802), LNCaP (Cat. # 89110211) and VCap (Cat. #
06020201) human prostate cancer cell lines were cultured in RPMI 1640 (Gibco) containing
2mM L-Glutamine and 10% foetal calf serum (FCS). The AR negative prostate cancer cell line
(PC3; Cat. # 90112714) was cultured in Ham’s F12 medium (Lonza) containing 2mM L-Gluta-
mine and 7% FCS.
Quantitative RT-PCR
Total RNA was extracted from mouse-depleted xenografts using Qiagen RNeasy mini-col-
umns, according to the manufacturer’s protocol. RNA was reverse transcribed, using random
hexamers (Invitrogen) and reverse transcriptase (Superscript II, Invitrogen). Real time PCR
was carried out using SSoFast EvaGreen Supamix (Biorad). Reactions were prepared following
manufacturer’s protocols. All reactions were carried out in triplicate on 96-well PCR plates in
a CFX96 real time PCR detection system and data analysis was performed using CFX manager
software (Bio-Rad). The following primer sets were used; flAR: 0 &&$*&77*&7***$*$*
&**0and ¶ &7**&*7**7*&*7&&&77& ¶, AR-V1: 0 &&$7&77*7&*7&77&*
*$$$7*77$7*$$*&0 and 0&7*77*7**$7*$*&$*&7*$*$*7&70 and 0 777&
77&$*7&&&$77**7*0, AR-V7: 0 &&$7&77*7&*7&77&**$$$7*77$7*$$*&0
and 0777*$$7*$**&$$*7&$*&&777&70, GAPDH: 0**$&$&**$$**&&$7*&
&$0 and 0 $$**7*$$**7&**$*7&$$0. 22RV1 cell cDNAwas used to create a stan-
dard curve. Relative expression was evaluated using the relative standard curve method; normaliz-
ing to GAPDH and a calibrator (LNCaP or PC3 cell line). AR variant primers were obtained from
Donald J Tindall, (Mayo Clinic, Minnesota, USA). Each sample was run in triplicate.
Whole exome sequencing and data analysis
Genomic DNA was extracted using Qiagen’s DNeasy Blood and Tissue kit from patient lym-
phocytes and mouse cell-depleted xenograft tumour cells. Whole exome sequencing was
performed by Eurofins Genomics. Sequencing of libraries was performed on a HiSeq2500
(Illumina).
Mutation calling. Read pairs were mapped against the human genome (build 38) using
BWA “mem” algorithm with default parameters [14]. The resulting bam files were then pre-
processed in preparation for somatic mutation detection using the Genome Analysis Toolkit
(GATK) v3.5 best practice pipeline [15] and dbsnp version 144 in the base recalibration step
[16]. MuTect v1.1.7 was then applied to compare the resulting bam files from tumour and
matched donor lymphocytes to call somatic mutations [17]. Mutations were annotated using
the Ensembl Variant Effect Predictor [18] and non-silent protein coding mutations taken for-
ward for further consideration. The somatic status of each SNV and their prevalence in clinical
prostate cancer samples was assessed using the COSMIC database [19].
Copy number profiling. As for the mutation calling, read pairs were mapped against
the human genome (build 38) using BWA “mem” algorithm with default parameters [14].
Duplicate reads were removed, as were reads achieving mapping quality below 37. Depth of
coverage at each position targeted by the Nextera Exome capture kit was calculated using
GATK “DepthOfCoverage” tool [15] and the resulting tumour and normal profiles input to
EBV-associated lymphomas from human prostate xenografts
PLOS ONE | https://doi.org/10.1371/journal.pone.0188228 November 16, 2017 4 / 18
ExomeCNV R package using default parameters [20]. Gene level log2 copy number ratios
were then parsed using custom Perl scripts, with those achieving |log2 ratio|> 0.50 taken for-
ward for further consideration.
Quantitative PCR
Genomic DNA was extracted using Qiagen’s DNeasy Blood and Tissue kit from patient mouse
cell-depleted xenograft tumour cells. EBV was detected by qPCR using the following primers;
EBNA-1 fwd $*$7*$&&&$**$*$$**&&&$$*& and EBNA-1 rev &$$$****$*$&*$&7&
$$7**7*7. The EBV copy number per cell was calculated by normalising the Cq to the single
copy gene GAPDH which was assessed using the following primers; GAPDH fwd $7*&7*&$
77&*&&&7&77$ and GAPDH rev *&*&&&$$7$&*$&&$$$7&.The assay utilised SsoFast
EvaGreen Supermix (Bio-Rad) primers at a final concentration of 400nM and 10ng of input
DNA. Samples were analysed on FrameStar1 96 well plates (4titude) using the CFX96 qPCR
system (Bio-Rad) and data analysis was performed using CFX manager 2.0 software (Bio-Rad).
Amplified products were identified on a 1.5% Agarose TBE gel.
To determine androgen receptor (AR) copy number the following primers were used:
AR fwd 7&$77$7&$**7&7$7&$$&7&77 and AR rev *7&$7&&&7*&77&$7$$&$77
7& and Dystrophin (DMD) fwd 77**77*&&$*77$7***&7, DMD rev &&$*&7*7&$7*&
$$$$&&& and GAPDH. The AR copy number per cell was calculated by normalizing the Cq
of the AR to that of GAPDH and DMD. DMD is located on the X-chromosome and was used to
distinguish between AR amplification and copy number alterations. Controls included female
DNA, donor lymphocytes and the cancer cell line VCaP, which has an amplified AR gene.
IgH gene rearrangement assay
Clonality was evaluated by PCR for V-J gene rearrangements of the IgH gene using the Identi-
Clone™ diagnostic kit from Invivoscribe. This kit has been validated for use in the diagnosis of
patients with suspected lymphoproliferation. The assay employs multiple consensus DNA
primers that target conserved genetic regions within the IgH gene. The test includes 6 master
mixes targeting the conserved framework (FR) of the variable (V) regions and the conserved
joining (J) regions, as well as the diversity (D) and joining regions. DNA bands were either
visualized on a non-denaturing 6% polyacrylamide TBE gel, or for downstream Sanger
sequencing, PCR products were loaded onto a 1.5% Agarose TBE gel.
Blue-white screening
Amplicons generated from the IgH assay were extracted from 1.5% agarose gels and purified
using the QIAquick Gel Extraction Kit according to the manufacturer’s instructions (Qiagen).
Products were ligated into the pGEM1-T Easy vector using the pGEM1-T Easy system (Pro-
mega), transformed into JM109 High Efficiency Competent Cells (Promega UK) and subse-
quently plated onto LB/carbenicillin/IPTG/X-Gal plates. Following amplification of individual
colonies plasmid DNA was extracted, checked for the presence of insert by restriction diges-
tion with EcoRI (Promega) and sequenced using Sanger sequencing (Applied Biosystems
3130XL) with M13-47 (&*&&$***7777&&&$*7&$&*$&) and M13 rev -26 (**$$$&$*&
7$7*$&&$7*) primers.
T-cell receptor gamma chain gene rearrangement assay
Clonality was evaluated by PCR for V-J gene rearrangements of the T cell receptor gamma
gene (TCRG) using the IdentiClone™ TCRG gene kit from Invivoscribe. This kit has been
EBV-associated lymphomas from human prostate xenografts
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validated for use in the diagnosis of patients with suspected lymphoproliferation. The assay
employs multiple consensus DNA primers that target conserved genetic regions within the
TCRG gene. The test includes 3 master mixes targeting the conserved flanking regions around
the V-J rearrangement. DNA bands were visualized on a non-denaturing 6% polyacrylamide
TBE gel.
Statistical analysis
Associations between tumour characteristics and various clinical parameters (Gleason grade,
tumour stage, hormone status, PSA status) were investigated using Fisher’s exact test. Repeated
Measures Parameter Analysis (InVivoStat) was used to assess tumour growth over time. Pair-
wise tests were carried out to assess the difference between predicted means. P<0.05 was con-
sidered significant for all statistical analysis.
Results
Establishment of xenografts from tumour fragments
Primary tumour fragments, from 147 patients, were implanted subcutaneously into
Rag2-/-čC-/-mice resulting in tumour outgrowths from 47 biopsies (32% primary outgrowth
rate). Seventeen patients (17 of 47 or 36%) from this cohort had not received any form of ther-
apy whereas the remaining 30 patients (64%) had received hormone therapy alone or hormone
treatment and radio/chemo therapy (15%). From 20 patients, we established and expanded 20
transplantable tumour lines for a minimum of 3 generations (14% take rate). Of those, seven
patients had not received any form of therapy, 10 had received hormone therapy alone and 3
had received hormone therapy and radio/chemotherapy (Table 1).
To evaluate which clinical characteristics correlated with tumour take the primary and sta-
ble xenograft outgrowth rates were compared across each clinical characteristic using Fisher’s
exact test. Stable xenograft development was most likely from patients who had undergone
hormone treatment (OR: 2.9, 95% CI: 1.1–8.1, P = 0.04), with only Gleason grade 7 and above
yielding stably transplantable xenografts.
PDX tissue was genotyped at primary outgrowth and at alternate generations using STR
profiling. A comparison was made with lymphocytes from the patient donor (S1 Table). Com-
plete concordance was observed for 15 models at all 16 loci. Chromosomal loss or deletions
was observed in models Y042, H427, Y019 & H455, with gains observed in model Y056. Whilst
all PDX tissues were confirmed to be patient-derived at the first generation, xenograft H070
was confirmed as exclusively murine at the fourth generation, and was excluded from the
study.
Latency (time from initial engraftment until establishment of a transplantable tumour line)
ranged from 3 to 18 months (median, 5 months, Table 1). Latency was not associated with
doubling time or donor pathology as tumour lines with the shortest latencies (3–4 months)
had doubling times which ranged from 4–22 days and were derived from hormone naive and
CRPC patients (Table 1).
Xenograft histopathology and molecular characteristics. We next evaluated whether
stable xenografts retained histologic features and biomarker expression patterns consistent
with prostate cancer. The diagnosis of prostate cancer and degree of tumour differentiation
was assessed by a uropathologist. The majority of stable lines were derived from patients who
had undergone androgen ablation making the assessment of these specimens difficult, due to
hormonal changes. Nonetheless, the xenografts derived from hormone naïve patients did not
resemble their matched patient tumour, specifically in the degree of differentiation (Fig 1,S1
Fig). All had features of poorly differentiated carcinoma, with nuclear atypia, high nuclear-to-
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cytoplasmic ratios and loss of glandular architecture. Only three xenograft lines matched their
patient donor in the degree of differentiation, and expression of biomarkers typical of prostate
adenocarcinoma (Fig 2, S1 Fig). Whilst the remaining seventeen lines were largely devoid of
cytokeratin and PSA expression, we observed expression of the flAR at the protein and RNA
level as well as expression of AR variants. (Table 1, S1 Fig, S2 Fig). Furthermore, we observed a
partial response to flutamide in 1 of 4 xenografts (Y042) and a small, but significant increase in
the rate of growth in the flutamide arm, in mice bearing H084 tumours (S2 Fig).
Genome instability is implicated in the development and progression of prostate cancer
and is a feature of many cancers [21, 22]. Xenografts were compared with their matching lym-
phocytes using whole exome sequencing to identify copy number aberrations and cancer gene
mutations. We were unable to perform a comparative analysis of the original tumours versus
Table 1. Characteristics of xenografts and corresponding donor tumours.
Sample
ID
Patient information Xenograft information
Age Pathology Hormone
Status
aLatency
(mo)
bDoubling
time (d)
AR Androgen
sensitivity
cflAR AR
Variants
dX
aneuploidy
AR
amplification
Y042 56 G3+4, T2 HN 4 4 + Partial + +
H016 67 G4+5, T3a HN 3 9 - No + +
H024 69 G4+3, T3b HN 5 9 - + +
H042 63 G3+4, T2c HN 4 22 - - +
H084 61 G4+3, T3a HN 7 25 + No
H082 53 G3+4, T3a HN 6 40 + No + +
H087 68 G3+4 HN 4 14 +
H050 60 G3+4, T2c,
b1
HR 6 21 - - -
H288 79 G4+3, T2c,
m1
HR 4 9 -
H070 70 G3+4, T2c HR 4 16 -
H027 68 G5+4, n1 HR 6 25 +
H107 71 G4+4, T2b HR 5 17 +
H427 69 G4+5, T3b,
n1, b1
HR 18 55 + + +
H460 76 T3 HR 7 14 - -
H493 68 G4+5, T3b,
n1, b1
HR 4 20 - -
Y019 70 G4+5 CRPC 5 7 - + + - -
Y018 75 HC CRPC 6 27 + - -
Y056 67 G5+4 CRPC 4 18 + + +
H149 78 G4+5, T4, n1,
m1
CRPC 12 15 +
H455 67 m1 CRPC 10 28 + + +
2mm core biopsies, from men undergoing radical prostatectomy or trans-urethral resection for prostate cancer, were engrafted, subcutaneously, into
Rag2-/-Ȗc-/- mice. All xenografts were derived from primary prostate cancer. Gleason score and stage, at biopsy are shown. HC = Hormone changes
following ADT. HN = Hormone nawve. HR = Donor hormone responsive at time of biopsy. CRPC = castrate-resistant prostate cancer.
atime taken for primary outgrowth until establishment of a transplantable tumour line.
btumour diameter doubling time of stable PDXs.
cexpression of flAR, ARV1 or ARV7 by qRT-PCR.
dX aneuploidy and AR amplification were determined by qPCR.
AR expression status refers to protein expression unless otherwise stated.
https://doi.org/10.1371/journal.pone.0188228.t001
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xenograft due to limiting amounts of patient tumour tissue. To avoid confounding signals,
xenografts with greater than 1% mouse component were excluded from the analysis. There
was little evidence for the presence of common prostate cancer SNVs (single nucleotide vari-
ants) in the PDX tumours other than TP53 (H455) (S2 Table). However, unsupervised hierar-
chical clustering of copy number segmentation profiles clearly showed H455 as an outlier and
the most aberrant in terms of copy number (Fig 3, S2 Table). Similar to previously published
prostate cancer studies [23], recurrent chromosomal abnormalities included losses on chro-
mosomes 10q (including PTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53),
18q, 6q and 9q (Fig 3, S2 Table). Significantly, the 3Mb deletion between ERG and TMPRSS2
Fig 1. Primary tumour xenografts derived from treatment-nawve human prostate tissue specimens.
H&E sections of representative prostate cancer xenografts and their corresponding human donor sample.
Note loss of glandular architecture.
https://doi.org/10.1371/journal.pone.0188228.g001
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on Ch21 was indicative of the TMPRSS2-ERG fusion product, a major molecular hallmark of
prostate cancer [21]. Gains included the q-arm of X, which was confirmed by PCR for AR
(Table 1). In contrast, no obvious prostate cancer associated changes were found for the
remaining xenografts, which together with the lack of prostate cancer markers and response to
castration prompted further investigation.
Epstein-Barr virus and lymphoma development in prostate cancer
xenografts
In 2015, Wetterauer and colleagues [24] published findings describing the development of
human lymphomas in a prostate cancer xenograft program. Given the importance of EBV in
the pathogenesis of lymphoproliferative disorders in immunocompromised humans we firstly
Fig 2. Primary tumour xenografts derived from human prostate tissue specimens demonstrating
typical features of prostate adenocarcinoma. H&E sections of human donor sample (upper panel) and
corresponding xenograft (lower panel). Xenograft tissue sections were stained with antibodies raised against
human AR (clone 441 at 1:50), PSA (1:25) and pan-cytokeratin (1:800). Human tissue, from patients with
BPH or cancer was used as a positive control. Non-specific signal was assessed using isotype controls and
secondary only antibodies. Xenograft images are from primary outgrowths (annotated as F1). Magnification
x400.
https://doi.org/10.1371/journal.pone.0188228.g002
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evaluated the xenografts for the presence of EBV DNA. We interrogated the sequences gener-
ated from exome sequencing and compared xenografts to donor lymphocytes (Fig 4A). The
total reads mapped to EBV were significantly higher in five of six xenografts compared to their
matched donor lymphocytes which we calculated as equivalent to 1–2 copies of the EBV
genome. In a larger series, we determined the presence of latent EBV infection by qPCR for
EBV nuclear antigen (EBNA); which is found in all EBV-related malignancies and is critical
Fig 3. Unsupervised hierarchical clustering of copy number segmentation profiles. PDX, H455 is as an outlier
and the most aberrant in terms of copy number. Table listing CNVs found in PDX H455.
https://doi.org/10.1371/journal.pone.0188228.g003
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for the replication of the episomal EBV genome [25]. As shown in Fig 4B, 16 of 19 (84%) PDX
were positive for latent EBV. We could exclude cross contamination between xenografts as the
source of EBV infection as STR profiling confirmed that the xenografts are genetically distinct
and identical to the patient donor (S1 Table).
To confirm that the source of latent EBV was due to the proliferation of human B lympho-
cytes we looked for immunoglobulin heavy chain (IgH) rearrangements which occur specifi-
cally in B lymphocytes during maturation (Fig 5A). Using a clinical diagnostic kit which
utilises a multiplex PCR targeting the VJD regions of the IgH gene we concluded that 15 of 16
EBV+ xenografts arose from a single B cell clone. We also verified that 3 EBV—xenografts
(H427, H455, H149) had not arisen from human B cells. To confirm these findings, in particu-
lar where there was some ambiguity (e.g. band was not prominent or just outside the valid size
range) we cloned and sequenced a number of amplicons (S3 Table). A subsequent BLAST
search showed that xenograft Y018 had not arisen from a B cell, despite its EBV status.
To exclude the possibility that the two remaining EBV+ xenografts (Y018, H149) arose
from clonal T cell populations, we tested for T-cell receptor gamma chain gene rearrange-
ments (which occur during T cell maturation) using a multiplex PCR targeting several V
regions within the gene locus. We established that the remaining PDXs had not arisen from a
T cell clone (Fig 5B). Further phenotypic analysis, using a combination of flow cytometry and
IHC, established that H107 and Y018 were unlikely to have arisen from NK cells, due to lack
Fig 4. EBV status of PDX lines. A. Total reads, generated from whole genome exome sequencing, mapped
to EBV. Donor Lymphocytes (open bars) were compared to PDX lines (solid bars). B. PCR amplification of
EBNA and GAPDH in PDX lines (upper panel). NTC = non template control. Lower panel; normalized EBNA
expression in PDX lines.
https://doi.org/10.1371/journal.pone.0188228.g004
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of reactivity for CD56 (Fig 6B). Nevertheless, we concluded that H107 is more typically lym-
phoblastic (CD45+/EpCAM-/ChrA-) whereas Y018, whilst not expressing EpCAM does
express the neuroendocrine marker Chromogranin A (Fig 6C). These analyses also confirmed
that the EBV- PDX were typically prostate cancer with some neuroendocrine features; such as
Chromogranin A expression, observed in xenograft H149 (Fig 6C).
Fig 5. IGH and T cell receptor gamma chain gene rearrangements in a PDX panel. A. PCR amplification of IGH gene VJD
regions using a multiplexed PCR. W = water control. + = B cell lymphoma clonal control.— = negative control (prostate epithelial
primary culture). Targets, FR1-JH: Y042 (L1) H016 (L2), H042 (L3), H084 (L4), H027 (L16), H288 (L17), H050 (L18), H024 (L19) are
within the valid size range (310-360bp). FR2-JH: H084 (L4), H027 (L16), H288 (L17), H050 (L18), H024 (L19) are within the valid
size range (250-295bp). FR3-JH: Y042 (L1), H016 (L2), H084 (L4), H082 (L5), H087 (L6), H460 (L9), Y018 (L12), H050 (L18), H024
(L19) are within the valid size range (100-170bp). DH-JH: H084 (L4), H087 (L6), H493 (L10), Y019 (L11), Y056 (L13) are within the
valid size range (110–290 and 390-420bp). DH7-JH: valid size range is 100-130bp B. PCR amplification of TCRG V-J regions using
a multiplexed PCR. W = water control. + = Positive controls (lanes 4 & 10; T cell lymphoma clonal controls),— = negative controls
(lane 3; prostate primary culture, lane 11; polyclonal control, lane 12; DU145 prostate cell line). Targets, VȖ1–8+ VȖ10, JȖ1.1,JȖ1.3,
JȖ2.1, JȖ2.3: Valid size range 145–255 bp. VȖ9+ VȖ11, JȖ1.1,JȖ1.3, JȖ2.1, JȖ2.3: Valid size range 80–220 bp.
https://doi.org/10.1371/journal.pone.0188228.g005
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Discussion
In the present study we aimed to generate human prostate cancer xenograft models to assess
their feasibility as preclinical models for drug screening and biomarker development. After
careful validation we established that only 2% of the biopsies engrafted resulted in a stable line,
resembling prostate cancer. The remaining stable xenografts were classified as donor-derived
lymphoma, associated with EBV.
Histologically, the xenografts did not resemble their matched donor tumour, particularly
from Gleason 7 disease. Our initial assessment of poorly differentiated adenocarcinoma was
based on reactivity for markers associated with prostate cancer. Chen and colleagues similarly
described atypical undifferentiated morphology from a series of xenografts generated in NSG
mice [26]. They reported sporadic reactivity for AR, cytokeratin and EpCAM and suggested
rare, undifferentiated clones from the donor tumour had established the xenograft. In support
of these data is the finding that establishment of human leukaemia in immunodeficient mice
Fig 6. Flow cytometric gating strategy and analysis of PDX panel for epithelial and haematopoietic
lineage markers. A. Serially transplantable PDX tumour were depleted of mouse cells before labelling with
human specific antibodies to CD44, CD45, CD19, CD56 and EPCaM. B. Table of percentage of cells
expressing specific markers. LNCaP was used as a positive control for EPCaM expression and PC3 was
used as a negative control for CD45, CD19 and CD56 expression. C. IHC of Chromogranin A expression in
PDX lines.
https://doi.org/10.1371/journal.pone.0188228.g006
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selects and expands a more aggressive malignancy, recapitulating the process of relapse in
patients. Comparisons of paired diagnosis and relapsed samples showed that with regard to
genetic lesions, xenograft leukaemias more closely resembled relapse samples than bulk diag-
nosis samples [27]. The partial response to flutamide and the presence of AR variants further
confounded the provenance of the xenografts. Whilst it has been reported that up to 70% of B
cell lymphomas express AR [28], we are not aware of any publications reporting expression of
AR variants in human lymphoma.
Our finding that there was little evidence for the presence of common prostate cancer
SNVs in the atypical prostate cancer xenografts prompted us to investigate further. We
screened for the presence of EBV because of its link with the pathogenesis of lymphoprolifera-
tive disorders. EBV is a human herpesvirus that infects over 90% of humans persisting for the
lifetime of immunocompetent individuals as an asymptomatic, latent infection of the B-lym-
phocyte pool. However, immunocompromised individuals, such as those receiving immuno-
suppressive drugs are at risk of developing B-cell lymphomas [29]. The presence of EBV could
not be confirmed in donor specimens due to the limited supply of tissue and we reasoned that
because of the efficiency of the immune system in suppressing EBV, in immunocompetent
individuals, we would not have detected the virus. In support of this, we did not detect EBV in
donor lymphocytes, but we were able to show, using STR profiling, that the xenografts were
human and matched their corresponding donor lymphocytes. The lymphomas that developed
in the initial transplantation were predominately from a B-cell lineage. However, two of the
EBV+ lines had neither B nor T cell rearrangements, yet were CD45+. Within the classification
of non-B lineage lymphoblastic lymphomas, 30% are divided into T-cell/NK bipotential pro-
genitors, early stage T-cell precursors without TCR rearrangements, and NK precursors [30].
It is possible that both lines are derived from an early stage T-cell precursor. However,
sequencing will be required to elucidate their origin.
The development of EBV-associated lymphoma from human solid tumour xenografts is
not a new phenomenon, but it is under reported. It has been described in urothelial cancer
[31], non-small cell lung cancers [32], hepatocellular carcinomas [33] and in prostate cancer
[24]. The frequency of lymphoma development ranged from 17% (in SCID mice) to 80% in
NSG/NOGmice. We observed a frequency of 82% in Rag2-/-čC-/-mice, suggesting that the
most severe immune deficient mouse models are more vulnerable to development of EBV-
driven lymphoma, presumably due to the absence of cytotoxic T cells which play a critical role
in the control of latent EBV infected B-cells [34].
The generation of serially-transplantable prostate cancer xenograft lines from primary spec-
imens has rarely been reported. Of the few successful studies most have been derived from
advanced metastatic specimens [35–39]. More recently Lin et al. [12] reported the establish-
ment of five xenografts from primary specimens, in NOD/SCID mice, with a success rate of
27%. They attributed the improved survival rate to grafting the specimen under the renal cap-
sule but did not carry out a comparison with other sites [12]. Nonetheless, it is likely that if the
donor is EBV seropositive, engraftment under the renal capsule site is unlikely to prevent
development of lymphoma. It has been suggested that this phenomenon might be avoided
through the use of implantable slow-release testosterone pellets [37]. However, we were unable
to prevent lymphoma development despite the use of androgen supplementation.
Conclusion
Taken together, these data highlight the importance of thorough characterisation of xenograft
outgrowths. We advocate early screening for EBV together with regular genotyping and
phenotyping for lymphoid and epithelial markers, to avoid lymphoma development from
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donor lymphocytes and overgrowth of stable PDX by murine cells. Whilst we were unable to
associate specific clinical characteristic with engraftment, due to the small numbers of stable
xenografts derived from this program, we were able to show that prostate tumours have signifi-
cantly longer latencies than lymphomas. Prostate cancer in humans is slow growing and it
appears that this is mirrored in the mouse, particularly for the least aggressive tumours.
Supporting information
S1 Fig. Primary tumour xenografts derived from treatment-naïve human prostate tissue
specimens. A.H&E sections of representative prostate cancer xenografts and their corre-
sponding human donor sample. . . B. Xenograft tissue sections stained with antibodies raised
against human AR (clone 441 at 1:50), PSA (1:25) and pan-cytokeratin (1:800). Human tissue,
from patients with BPH or cancer was used as a positive control. Non-specific signal was
assessed using isotype controls and secondary only antibodies. Xenograft images are from pri-
mary outgrowths (annotated as F1). Magnification x400.
(TIF)
S2 Fig. Androgen sensitivity of xenograft lines derived from hormone naïve donors: A.
Quantitative RT-PCR for flAR, variants AR-V1 and AR-V7. The results are expressed as nor-
malised values (to GAPDH and a calibrator (LNCaP for AR-V7) or PC3 for flAR, and AR-V1.
Each sample was run in triplicate and error bars represent mean ± SD of technical replicates.
Unpaired, two-tailed T-tests were run to determine differences between cell lines and PDXs.
P<0.001. B. Response of PDX lines to placebo (open bars) and the anti-androgen, flutamide
(closed bars). Tumour response was calculated from the slope of log10 transformed tumour
growth curves.  P<0.0001, unpaired t-test. B. C.
(TIF)
S1 Table. PDX (between P1-P10) were validated as unique to the patient donor by short
tandem repeat (STR) DNA fingerprinting using the Promega Powerplex 16 system. The
STR profiles were matched to their respective lymphocyte DNA.–indicates loss of specific loci.
(DOCX)
S2 Table. Single nucleotide variants (SNVs) and mutations for PDX H455.
(XLSX)
S3 Table. Verification of human IgH gene rearrangements from PCR amplicons. Results of
Blast search from Sanger sequences.
(DOCX)
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